IL-17 release from primary human PBMC
This open innovation assay is being developed for psoriasis to asses IL-17 release from human primary PBMC.
The cytokine IL-17 is a main driver of psoriasis pathophysiology and can be produced by several cells including human Peripheral Blood Mononuclear Cells (PBMC). This open innovation assay is currently being developed with the aim to establish a simple, robust and predictive model for IL-17 release. Primary human PBMC are stimulated by CD3 and CD28 activation and IL-17, IFN-gamma and cell viability is measured at the end of the incubation with test compound.